GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alpha Teknova Inc (NAS:TKNO) » Definitions » ROE %

Alpha Teknova (Alpha Teknova) ROE % : -44.94% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Alpha Teknova ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Alpha Teknova's annualized net income for the quarter that ended in Dec. 2023 was $-42.62 Mil. Alpha Teknova's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $94.84 Mil. Therefore, Alpha Teknova's annualized ROE % for the quarter that ended in Dec. 2023 was -44.94%.

The historical rank and industry rank for Alpha Teknova's ROE % or its related term are showing as below:

TKNO' s ROE % Range Over the Past 10 Years
Min: -39.31   Med: -12.26   Max: 24.06
Current: -39.31

During the past 5 years, Alpha Teknova's highest ROE % was 24.06%. The lowest was -39.31%. And the median was -12.26%.

TKNO's ROE % is ranked worse than
82.95% of 997 companies
in the Drug Manufacturers industry
Industry Median: 4.2 vs TKNO: -39.31

Alpha Teknova ROE % Historical Data

The historical data trend for Alpha Teknova's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpha Teknova ROE % Chart

Alpha Teknova Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
-10.11 24.06 -12.26 -39.05 -38.73

Alpha Teknova Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -50.19 -36.74 -32.10 -43.70 -44.94

Competitive Comparison of Alpha Teknova's ROE %

For the Drug Manufacturers - Specialty & Generic subindustry, Alpha Teknova's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alpha Teknova's ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alpha Teknova's ROE % distribution charts can be found below:

* The bar in red indicates where Alpha Teknova's ROE % falls into.



Alpha Teknova ROE % Calculation

Alpha Teknova's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-36.78/( (99.885+90.036)/ 2 )
=-36.78/94.9605
=-38.73 %

Alpha Teknova's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-42.624/( (99.652+90.036)/ 2 )
=-42.624/94.844
=-44.94 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Alpha Teknova  (NAS:TKNO) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-42.624/94.844
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-42.624 / 31.468)*(31.468 / 133.486)*(133.486 / 94.844)
=Net Margin %*Asset Turnover*Equity Multiplier
=-135.45 %*0.2357*1.4074
=ROA %*Equity Multiplier
=-31.93 %*1.4074
=-44.94 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-42.624/94.844
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-42.624 / -43.84) * (-43.84 / -34.756) * (-34.756 / 31.468) * (31.468 / 133.486) * (133.486 / 94.844)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.9723 * 1.2614 * -110.45 % * 0.2357 * 1.4074
=-44.94 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Alpha Teknova ROE % Related Terms

Thank you for viewing the detailed overview of Alpha Teknova's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Alpha Teknova (Alpha Teknova) Business Description

Traded in Other Exchanges
N/A
Address
2451 Bert Drive, Hollister, CA, USA, 95023
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification.
Executives
Ken Gelhaus officer: Chief Commercial Officer 2290 BERT DRIVE, HOLLISTER CA 95023
Stephen Gunstream director, officer: See Remarks 2290 BERT DRIVE, HOLLISTER CA 95023
J Matthew Mackowski director 343 SANSOME ST, SUITE 1215, SANSASAN FRANCISCO CA 94104
Matthew Lowell officer: Chief Financial Officer 2290 BERT DRIVE, HOLLISTER CA 95023
Damon Terrill officer: See Remarks 2290 BERT DRIVE, HOLLISTER CA 95023
Thp Iv Affiliates Fund, Llc 10 percent owner 360 POST STREET, SUITE 601, SAN FRANCISCO CA 94108
Martha J Demski director 7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122
Lisa Hood officer: Chief People Officer 2290 BERT DRIVE, HOLLISTER CA 95023
Irene Davis director 2290 BERT DRIVE, HOLLISTER CA 95023
Ted Davis director 2290 BERT DRIVE, HOLLISTER CA 95023
Telegraph Hill Partners Iv, L.p. 10 percent owner 360 POST STREET, SUITE 601, SAN FRANCISCO MA 94108
Paul David Grossman director 1600 FARADAY AVENUE, CARLSBAD CA 92008
Brett Robertson director C/O INVUITY, INC., 444 DE HARO STREET, SAN FRANCOSCO CA 94107
Alexander C. Herzick director 2290 BERT DRIVE, HOLLISTER CA 95023
Telegraph Hill Partners Management Company, Llc 10 percent owner 360 POST STREET, SUITE 601, SAN FRANCISCO CA 94108